ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
IGF2-associated tumor cells and APOE-positive macrophages define an imatinib resistance-associated niche in gastrointestinal stromal tumors.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundGastrointestinal stromal tumors (GISTs) are highly responsive to imatinib, but acquired resistance frequently develops. In particular, the roles of distinct tumor cells and their interactions with tumor-associated macrophages (TAMs) in shaping imatinib response remain poorly understood.
methodsWe used integrative single-cell transcriptomic analysis to characterize tumor cells and tumor microenvironment heterogeneity in gastric GIST, with validation in independent imatinib-treated, metastatic, and spatial transcriptomic datasets. Cell-cell communication, metabolic pathway, in silico perturbation, and connectivity analyses were performed to identify resistance-associated microenvironmental programs.
resultsWe identified five transcriptionally distinct GIST tumor-cell states with distinct functional programs. Among them, the S100A6-associated and IGF2-associated states showed opposing associations with imatinib response and distinct relationships with TAM programs. A niche comprising S100A6-associated tumor cells and CCL4-positive TAMs was observed in imatinib-sensitive tumors and exhibited stress-response and immune-activation features. In contrast, the IGF2-associated state was enriched in imatinib-resistant and metastatic GIST samples and showed coordinated occurrence with APOE-positive TAMs in a resistance-associated niche characterized by metabolic remodeling and immunoregulatory features, with predicted IGF and KIT signaling and iron-related metabolic crosstalk. This tumor-cell state also showed predicted immunosuppressive interactions with regulatory T cells. Integrative perturbation analysis identified a 61-gene resistance-associated signature, with IFI6 emerging as top-ranked candidate marker.
conclusionsThese findings reveal distinct tumor-cell-macrophage niches underlying imatinib sensitivity and resistance in GIST, and identify the IGF2-associated GIST tumor-cell state-APOE-positive TAM axis as a candidate resistance-associated tumor-immune state with potential biomarker and therapeutic implications.
Indexed as
Identifiers
42758452What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.